Skip to main content
Back to AI Intelligence Briefing
RegulationAugust 20, 2026Source: U.S. Food and Drug Administration

FDA Seeks Public Feedback to Inform Regulatory Approach for Generative AI-Enabled Medical Devices

The FDA has released a discussion paper outlining regulatory considerations for generative AI-enabled medical devices, including frameworks for risk assessment, premarket evaluation, and postmarket monitoring. The agency is inviting comments from manufacturers, clinicians, researchers, and the public to shape policy for clinical AI tools, with feedback due by October 19, 2026.

LOG Standards provides this short context and directs readers to the named publisher for the complete report. The source article remains the authoritative account of the underlying reporting.
Read Full Article

About LOG Standards

LOG Standards provides an independent accreditation signal for AI models used in healthcare, helping hospitals, care networks, and AI companies bring clinical AI readiness and governance into clearer conversations.

Our AI Intelligence Briefing tracks the latest developments in AI safety, AI in medicine, mental health AI, clinical AI governance, and regulatory policy — keeping healthcare stakeholders informed about the rapidly evolving AI landscape.